Company intelligence / Profile preview

Eleusis

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Eleusis developed IV formulations of psychedelic compounds (notably psilocin/psilocybin), completed Phase 1 trial of LSD showing tolerability, and planned/initiated Phase 1 for intravenous psilocin (ELE-101/ELE-Psilo) for depression; pipeline included early anti-inflammatory psychedelic research (e.g., new analogs like DOI) but that research deprioritized following Beckley Psytech acquisition

Therapeutic areas: CardiovascularImmunologyOphthalmologyEndocrinologyNeurologyDermatologyPsychiatry
Modalities: Small moleculePsychedelicBiologic (potential/early research)
Industry: Biotech

Partnerships

Academic: Collaborations with Louisiana State University researchers David and Charles NicholsIndustry: None directly reported; now integrated with Beckley Psytech

Beyond the preview

Go deeper on Eleusis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eleusis.

Explore the full profile